Documents

Strong order intake and U.S. deals offset Diagnostics weakness; outlook and spin-off plans updated.

Strong equipment orders and innovation offset Diagnostics weakness; FY2026 EPS guidance raised.

Q3 outlook: moderate Imaging growth, margin pressure from FX/inflation, and easing tariff impact.

Diagnostics faces China-driven decline, but core business and innovation drive future growth.

Strong Imaging and Precision Therapy growth offset Diagnostics headwinds; FY2026 outlook trimmed.

Q2 revenue and margins face headwinds from FX, tariffs, and China market challenges.

Strong Imaging and Precision Therapy growth offsets Diagnostics' China-driven decline; H2 outlook positive.

Strong imaging and precision therapy growth offset diagnostics headwinds, supporting 2026 outlook.

AI-powered imaging and precision therapy drive growth amid strong recurring revenues and innovation.

Imaging and Precision Therapy to grow 6%-9% annually, Diagnostics targets margin expansion, and AI drives innovation.

Solid growth and strong order intake continue, with tariff headwinds to be fully mitigated.

Guidance for 2026 targets 5%-6% revenue growth and resilient margins despite tariff and FX headwinds.

Q4 remains strong, but FX and tariffs pose significant headwinds for 2025 and 2026.

Strong Q3 growth and upgraded outlook offset by 2026 tariff headwinds; innovation drives optimism.

Q3 delivered strong growth and margin gains, prompting a raised FY25 outlook despite tariff risks.

Q3 revenue growth is guided at 5-6%, with flat margins and ongoing currency and tariff risks.